This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
The Netherlands Area Biotech Discussion Group - May 2020
Share |

20 May 2020 (16:00 - 17:30)

Virtual Meeting


 
Thank you to everyone who joined us for
 

COVID-19 Vaccine Discovery at Janssen

 

Lucy Rutten

and

Danielle van Manen

Janssen Vaccines & Prevention

COVID-19 is an infectious disease caused by SARS-coronavirus 2 (SARS-CoV-2) which attacks the respiratory system. On March 11th COVID-19 was declared a global pandemic having today infected over 4 million people across the world of which more than 290,000 have died. As part of Johnson and Johnson's multi-pronged approach to fight COVID-19, Janssen is developing a vaccine against COVID-19 leveraging our proven AdVac® and PER.C6® platforms. A lead COVID-19 vaccine candidate was identified, and manufacturing for clinical trials has started. The expectation is to initiate human clinical studies of the lead vaccine candidate at the latest by September 2020, with clinical data on safety and efficacy available by the end of the year. This could allow COVID-19 vaccine availability for emergency use in early 2021, a substantially accelerated time frame in comparison to the typical vaccine development process.


Lucy Rutten studied Biomedical Sciences in Leiden. Her major subject was Protein Crystallography. She acquired her PhD and carried out a Veni project at Crystal and Structural Chemistry in Utrecht (from 1997-2007), characterizing several bacterial outer membrane proteins. Subsequently she worked at Structural Neurobiology (KU Leuven), Belgium and for Crossbeta Biosciences in Utrecht, both for a year. She then made a sidestep to select antibodies against HIV using phage display at Biomolecular Imaging (Utrecht University) and QVQ. August 2014, she started working in Leiden for Janssen Vaccines & Prevention, part of Johnson & Johnson where she is leading the HIV-team designing a structure-based vaccine against HIV, which is currently on hold, because she and her team are now fully dedicated to the development of a SARS-CoV-2 vaccine.


 



 
 



20 May 2020
16:00 - 17:30
 
For more information on upcoming programs, please visit 
the Netherlands Area Biotech (NLab) Discussion Group homepage, 
here

 

 


 
more Calendar

9/14/2020 » 9/17/2020
Mass Spec 2020

9/28/2020 » 10/1/2020
CE Pharm 2020

Membership Software Powered by YourMembership  ::  Legal